

# UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

**FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO APPLICATION NO. 09/282,679 **FALO** 214001-00703 03/31/99 L **EXAMINER** 003705 HM22/0705 ECKERT SEAMANS CHERIN & MELLOTT VANDER VEGT, F 600 GRANT STREET PAPER NUMBER **ART UNIT** 44TH FLOOR PITTSBURGH PA 15219 1644 **DATE MAILED:** 07/05/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

U.S. G.P.O. 1999 460-693

PTO-90C (Rev. 2/95)

## Office Action Summary

Application No. 09/282,679 Applicant(s)

Falo et al

Examiner

F. Pierre VanderVegt

Group Art Unit 1644



Responsive to communication(s) filed on <i>Apr 21, 2000</i> This action is FINAL.  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.  A shortened statutory period for response to this action is set to expire			
		Disposition of Claim	
			jø/are pending in the application.
		Of the above, claim(s) 14-36	/are withdrawn from consideration.
Claim(s)	is/are allowed.		
Claim(s)			
	are subject to restriction or election requirement.		
Application Papers  See the attached Notice of Draftsperson's Patent Drain The drawing(s) filed on	objected to by the Examiner.  is approved disapproved.  er.  prity under 35 U.S.C. § 119(a)-(d).  ies of the priority documents have been  I Number)  in the International Bureau (PCT Rule 17.2(a)).		
Attachment(s)  Notice of References Cited, PTO-892  Information Disclosure Statement(s), PTO-1449, Pap  Interview Summary, PTO-413  Notice of Draftsperson's Patent Drawing Review, PTO  Notice of Informal Patent Application, PTO-152			
SEE OFFICE ACTION	ON THE FOLLOWING PAGES		

Application/Control Number: 09/282,679

Art Unit: 1644

Page 2

#### **DETAILED ACTION**

This application is a continuation-in-part of application S.N. 09/030,985, which claims priority to provisional application 60/039,472.

Claims 1-36 are currently pending in this application.

5

#### Election/Restriction

1. <u>Claims 14-36 stand withdrawn</u> from further consideration by the Examiner, 37 CFR 1.142(b), as being drawn to non-elected inventions, the requirement having been traversed in Paper No. 6.

<u>Claims 1-13 remain as the subject of examination</u> in the present Office Action.

2. In view of the amendment filed April 24, 2000, no outstanding rejections are maintained. THIS ACTION IS **NON-FINAL**.

15

10

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless --

20

25

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the Applicant for a patent.
- 3. Claims 1-13 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Moser et al (N on form PTO-892).

The Moser et al reference teaches fusion of murine dendritic-like cells with murine mastocytoma cells (Abstract in particular). Moser et al also teaches the fusion of human dendritic-like cells with human osteosarcoma cells to form a human dendritic/tumor hybrid cell line at a 2:1 ratio (Examples 7-9, pages 30-31 in particular). Moser et al further teaches the in vitro use of the hybridoma cells for priming autologous T cells before reinfusion of the T cells for an anti-tumor response (Abstract and claims 23-24 in particular) The prior art teaching clearly

Application/Control Number: 09/282,679

Art Unit: 1644

Page 3

anticipates the claimed invention. Claims 7, 8, 10 and 11 are included because the instant claims are drawn to the generation of antigen-specific T cells, not to the fusion procedure, and absent any showing to the contrary by Applicant, the ratio of dendritic to tumor cells is not seen as being as being a critical factor in the ability of the hybridomas to stimulate the T cells.

5

10

15

#### Conclusion

4. Papers related to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The fax phone number for official documents to be entered into the record for Art Unit 1644 is (703)305-3014.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to F. Pierre VanderVegt, whose telephone number is (703)305-6997. The Examiner can normally be reached Tuesday through Friday and odd-numbered Mondays (on year 2000 366-day calender) from 6:30 am to 4:00 pm ET. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Christina Chan can be reached at (703)308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist, whose telephone number is (703)308-0196.

20

F. Pierre VanderVegt, Ph.D. Patent Examiner Technology Center 1600 July 3, 2000

> F. PIERRE VANDERVEGT PATENT EXAMINER